Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have become the standard of care for first-line (1L) treatment of advanced NSCLC (aNSCLC) without actionable oncogenic driver mutations3. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.